<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886106</url>
  </required_header>
  <id_info>
    <org_study_id>RemiAnes 1</org_study_id>
    <nct_id>NCT00886106</nct_id>
  </id_info>
  <brief_title>The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers</brief_title>
  <acronym>RemiAnes 1</acronym>
  <official_title>The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of chronic pain is a major clinical challenge since chronic pain is frequent and
      leads to deterioration of quality of life. An injury or wound can lead to long term changes
      in the nervous system that make the skin more sensitive at and near the injury; this is
      termed hyperalgesia and occurs through long term depotentiation (LTP), i.e., a change in the
      synaptic interaction between neurons.

      Opioids are the gold standard for the symptomatic therapy of moderate to severe pain. Now, in
      animal studies the investigators have discovered previously unrecognized effects of opioids.

      Intradermal injection of capsaicin (injection of pepper extract into the skin) is an
      established pain model in humans. The investigators want to test the influence of
      remifentanil, an ultra-short acting opioid, on hyperalgesia observed after intradermal
      capsaicin in human volunteers in a double blind cross-over prospective active placebo
      controlled clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area of pin prick hyperalgesia</measure>
    <time_frame>0-6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain immediately after injection</measure>
    <time_frame>0-15 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulus-response (SR) function to a set of modified rigid von Frey filaments (8-512 mN)</measure>
    <time_frame>0-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heat pain threshold within the area of mechanical hyperalgesia</measure>
    <time_frame>0-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical pain threshold within the area of pin prick hyperalgesia, area of dynamic allodynia to brush</measure>
    <time_frame>0-6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>30 and 59 min after infusion of study medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remifentanil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women, aged between 19 and 40 years

          -  Body mass index between 15th and 85th percentile

          -  Normal findings in the medical history and physical examination

          -  Drug free for 1 week prior to the study day

        Exclusion Criteria:

          -  Regular use of medication especially analgesics

          -  Abuse of alcoholic beverages, drug abuse

          -  History of asthma

          -  Participation in a clinical trial in the 2 weeks preceding the study

          -  Symptoms of a clinically relevant illness in the 2 weeks before the first study day

          -  Resting systolic blood pressure &gt; 135 mmHg or diastolic blood pressure &gt; 85 mmHg

          -  Acute skin diseases like sunburn on the relevant areas or skin lesions

          -  Pregnancy or breast feeding

          -  Regular consumption of very spicy (capsaicin containing) food

          -  Allergy against any medication used in the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burkhard Gustorff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Andreae, MD</last_name>
    <phone>+436769677181</phone>
    <email>michael@andreae.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Stellnberger, MD</last_name>
    <phone>+436507333189</phone>
    <email>stephan.stellnberger@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesia, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Andreae, MD</last_name>
      <phone>+436769677181</phone>
      <email>michael@andreae.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Stellnberger, MD</last_name>
      <phone>+436507333189</phone>
      <email>stephan.stellnberger@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Astrid Chiari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Burkhard Gustorff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael H Andreae, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Stellnberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanna Opelt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Sandkuehler, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Drdla, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>November 17, 2009</last_update_submitted>
  <last_update_submitted_qc>November 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Burkhard Gustorff</name_title>
    <organization>Medical University of Vienna, Dept. Anaesthesia</organization>
  </responsible_party>
  <keyword>Capsaicin</keyword>
  <keyword>Remifentanil</keyword>
  <keyword>Hyperalgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

